Congestive Heart Failure (CHF) Pipeline Analysis”
gives comprehensive insight on the various drugs being developed for the
treatment of CHF. The report covers all the drugs being developed in various
development phases (Discovery to Phase 2 clinical). The pipeline focuses on
disease modification and includes pharmacologic drugs, gene therapy, stem cell
therapy and RNA-based therapeutics, but excludes symptom relief drugs like
diuretics, acute treatments, angiotensins or thrombin inhibitors etc. The report
also covers some of the hot targets in research for CHF treatments.
This report enables Pharmaceutical /Biotech
companies, Academic institutes, Individual researchers, Investors, Medical
technology companies, Service providers and other associated stake holders to
identify and analyze the available licensing/collaborative opportunities in the
CHF Drug market. The report also provide strategic insights on medicines that
are likely to have an impact on CHF treatment space and potentially alter
standards of care in CHF in the foreseeable future.
Current therapies focuses only to slow down the
progression of the disease as more number of molecules are symptom relieving
drugs, hence it provides a tremendous opportunity for upcoming therapies
specific to CHF such as gene-based, stem cell-based and miRNA-based therapies,
which reverses disease course and reduce the number of cardiac events.
Spanning over 112 pages, “Congestive Heart Failure -
Pipeline Analysis” report covers Report
Description, Epidemiology, Market Data, Pipeline Analysis, Genetherapy,
Stemcell Therapy, RNA Based Therapeutics, Drugs (Small Molecules, Recombinant
Proteins, Growth Factors), Hot Targets In Research, Major Players, References. The report covered companies are - Bayer Ag,
Bioheart, Inc., Celladon Corp, Coretherapix, Glaxosmithkline, Juventas
Therapeutics, Merck & Co., Miragen Therapeutics, Moderna Therapeutics, Nano
Cor Therapeutics, Ono Pharmaceuticals
For further information on this report, please visit-
http://mrr.cm/4mD
Find
all Diagnostics Reports at: http://www.marketresearchreports.com/diagnostics
No comments:
Post a Comment
Note: only a member of this blog may post a comment.